Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Maintains and Partially Improves Visual Function in Patients with Advanced Retinitis Pigmentosa
Restricted accessResearch articleFirst published online August, 2020
Intravenous Infusion of Umbilical Cord Mesenchymal Stem Cells Maintains and Partially Improves Visual Function in Patients with Advanced Retinitis Pigmentosa
Retinitis pigmentosa (RP) is a hereditary retinal degeneration disease with no effective therapeutic approaches. Inflammatory and immune disorders are thought to play an important role in the pathogenesis of RP. Human umbilical cord mesenchymal stem cells (UCMSCs), with multiple biological functions such as anti-inflammation and immunoregulation, have been applied in different systemic diseases. We conducted a phase I/II clinical trial aiming to evaluate the safety and efficacy of intravenous administration of UCMSCs in advanced RP patients. All 32 subjects were intravenously infused with one dose of 108 UCMSCs and were followed up for 12 months. No serious local or systemic adverse effects occurred in the whole follow-up. Most patients improved their best corrected visual acuity (BCVA) in the first 3 months. The proportions of patients with improved or maintained BCVA were 96.9%, 95.3%, 93.8%, 95.4%, 90.6%, and 90.6% at the 1st, 2nd, 3rd, 6th, 9th, and 12th month follow-up, respectively. Most of the patients (81.3%) maintained or improved their visual acuities for 12 months. The average NEI VFQ-25 questionnaire scores were significantly improved at the third month (P < 0.05). The average visual field sensitivity and flash visual evoked potential showed no significant difference (P = 0.185, P = 0.711). Our results indicated that the intravenous infusion of UCMSCs was safe for advanced RP patients. Most of the patients improved or maintained their visual functions in a long term. The life qualities were improved significantly in the first 3 months, suggesting that the intravenous infusion of UCMSCs may be a promising therapeutic approach for advanced RP patients.
Get full access to this article
View all access options for this article.
References
1.
ZhangQ. (2016). Retinitis Pigmentosa: Progress and Perspective. Asia Pac J Ophthalmol (Phila), 5:265–271.
2.
LiZY, PossinDE and MilamAH. (1995). Histopathology of bone spicule pigmentation in retinitis pigmentosa. Ophthalmology, 102:805–816.
3.
HartongDT, BersonEL and DryjaTP. (2006). Retinitis pigmentosa. Lancet, 368:1795–1809.
4.
BeltranWA, CideciyanAV, LewinAS, IwabeS, KhannaH, SumarokaA, ChiodoVA, FajardoDS, RomanAJ, et al. (2012). Gene therapy rescues photoreceptor blindness in dogs and paves the way for treating human X-linked retinitis pigmentosa. Proc Natl Acad Sci U S A, 109:2132–2137.
5.
FarrarGJ, KennaPF and HumphriesP. (2002). On the genetics of retinitis pigmentosa and on mutation-independent approaches to therapeutic intervention. EMBO J, 21:857–864.
6.
McclementsME and MaclarenRE. (2013). Gene therapy for retinal disease. Transl Res J Lab Clin Med, 161:241–254.
7.
WenR, inventor;US, assignee. Methods of Treatment for Retinal Diseases 2014.
8.
Weissmiller AM. (2012). Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl Neurodegener, 1:14.
9.
Miraldi UtzV, CoussaRG, AntakiF and TraboulsiEI. (2018). Gene therapy for RPE65-related retinal disease. Ophthalmic Genet, 39:671–677.
10.
PierceEA and BennettJ. (2015). The Status of RPE65 Gene Therapy Trials: Safety and Efficacy. Cold Spring Harb Perspect Med, 5:a017285.
11.
RodriguesGA, ShalaevE, KaramiTK, CunninghamJ, SlaterNKH and RiversHM. (2018). Pharmaceutical development of AAV-based gene therapy products for the eye. Pharm Res, 36:29.
12.
Apte RS. (2018). Gene therapy for retinal degeneration. Cell, 173:5.
13.
CampochiaroPA and MirTA. (2018). The mechanism of cone cell death in Retinitis Pigmentosa. Prog Retin Eye Res, 62:24–37.
14.
AthanasiouD, AguilaM, BellinghamJ, LiW, McCulleyC, ReevesPJ and CheethamME. (2018). The molecular and cellular basis of rhodopsin retinitis pigmentosa reveals potential strategies for therapy. Prog Retin Eye Res, 62:1–23.
15.
YoshidaN, IkedaY, NotomiS, IshikawaK, MurakamiY, HisatomiT, EnaidaH and IshibashiT. (2013). Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology, 120:100–105.
16.
StrongS, LiewG and MichaelidesM. (2017). Retinitis pigmentosa-associated cystoid macular oedema: pathogenesis and avenues of intervention. Br J Ophthalmol, 101:31–37.
17.
NarayanDS, WoodJP, ChidlowG and CassonRJ. (2016). A review of the mechanisms of cone degeneration in retinitis pigmentosa. Acta Ophthalmol, 94:748–754.
18.
XiuyingLI, BaiJ, XiaofengJI, RongguiLI, XuanY and WangY. (2014). Comprehensive characterization of four different populations of human mesenchymal stem cells as regards their immune properties, proliferation and differentiation. Int J Mol Med, 34:695–704.
19.
Nagamura-InoueT and HeH. (2014). Umbilical cord-derived mesenchymal stem cells: their advantages and potential clinical utility. World J Stem Cells, 6:195–202.
20.
ZouJP, HuangS, PengY, LiuHW, ChengB, FuXB and XiangXF. (2012). Mesenchymal stem cells/multipotent mesenchymal stromal cells (MSCs): potential role in healing cutaneous chronic wounds. Int J Low Extrem Wounds, 11:244–253.
21.
FriedmanR, BetancurM, BoisselL, TuncerH, CetruloC and KlingemannH. (2007). Umbilical cord mesenchymal stem cells: adjuvants for human cell transplantation. Biol Blood Marrow Transplant, 13:1477–1486.
22.
RiordanNH, MoralesI, FernandezG, AllenN, FearnotNE, LeckroneME, MarkovichDJ, MansfieldD, AvilaD, et al. (2018). Clinical feasibility of umbilical cord tissue-derived mesenchymal stem cells in the treatment of multiple sclerosis. J Transl Med, 16:57.
23.
MukaiT, TojoA and Nagamura-InoueT. (2018). Mesenchymal stromal cells as a potential therapeutic for neurological disorders. Regen Ther, 9:32–37.
24.
BartolucciJ, VerdugoFJ, GonzalezPL, LarreaRE, AbarzuaE, GosetC, RojoP, PalmaI, LamichR, et al. (2017). Safety and efficacy of the intravenous infusion of umbilical cord mesenchymal stem cells in patients with heart failure: a phase 1/2 randomized controlled trial (RIMECARD trial [Randomized clinical trial of intravenous infusion umbilical cord mesenchymal stem cells on cardiopathy]). Circ Res, 121:1192–1204.
25.
SatarianL, NouriniaR, SafiS, KanaviMR, JarughiN, DaftarianN, ArabL, AghdamiN, AhmadiehH and BaharvandH. (2017). Intravitreal injection of bone marrow mesenchymal stem cells in patients with advanced retinitis pigmentosa; a Safety Study. J Ophthalmic Vis Res, 12:58–64.
26.
QuL, GaoL, XuH, DuanP, ZengY, LiuY and YinZQ. (2017). Combined transplantation of human mesenchymal stem cells and human retinal progenitor cells into the subretinal space of RCS rats. Sci Rep, 7:199.
27.
SiqueiraRC, MessiasA, MessiasK, ArcieriRS, RuizMA, SouzaNF, MartinsLC and JorgeR. (2015). Quality of life in patients with retinitis pigmentosa submitted to intravitreal use of bone marrow-derived stem cells (Reticell -clinical trial). Stem Cell Res Ther, 6:29.
28.
OzmertE and ArslanU. (2020). Management of retinitis pigmentosa by Wharton's jelly derived mesenchymal stem cells: preliminary clinical results. Stem Cell Res Ther, 11:25.
29.
DingSLS, KumarS and MokPL. (2017). Cellular reparative mechanisms of mesenchymal stem cells for retinal diseases. Int J Mol Sci, 18:1406.
30.
NgTK, FortinoVR, PelaezD and CheungHS. (2014). Progress of mesenchymal stem cell therapy for neural and retinal diseases. World J Stem Cells, 6:111–119.
31.
TibbettsMD, SamuelMA, ChangTS and HoAC. (2012). Stem cell therapy for retinal disease. Curr Opin Ophthalmol, 23:226–234.
32.
WangS, LuB, GirmanS, DuanJ, McFarlandT, ZhangQS, GrompeM, AdamusG, AppukuttanB and LundR. (2010). Non-invasive stem cell therapy in a rat model for retinal degeneration and vascular pathology. PLoS One, 5:e9200.
33.
GuX, YuX, ZhaoC, DuanP, ZhaoT, LiuY, LiS, YangZ, LiY, et al. (2018). Efficacy and safety of autologous bone marrow mesenchymal stem cell transplantation in patients with diabetic retinopathy. Cell Physiol Biochem, 49:40–52.
34.
BersonEL, SandbergMA, RosnerB, BirchDG and HansonAH. (1985). Natural course of retinitis pigmentosa over a three-year interval. Am J Ophthalmol, 99:240–251.
35.
GroverS, FishmanGA, AndersonRJ, AlexanderKR and DerlackiDJ. (1997). Rate of visual field loss in retinitis pigmentosa. Ophthalmology, 104:460–465.
36.
Marmor MF. (1991). Visual acuity and field loss in retinitis pigmentosa. Arch Ophthalmol, 109:13–14.
37.
BersonEL, RosnerB, Weigel-DiFrancoC, DryjaTP and SandbergMA. (2002). Disease progression in patients with dominant retinitis pigmentosa and rhodopsin mutations. Invest Ophthalmol Vis Sci, 43:3027–3036.
38.
DominiciM, Le BlancK, MuellerI, Slaper-CortenbachI, MariniF, KrauseD, DeansR, KeatingA, ProckopD and HorwitzE. (2006). Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy, 8:315–317.
39.
MajoreI, MorettiP, StahlF, HassR and KasperC. (2011). Growth and differentiation properties of mesenchymal stromal cell populations derived from whole human umbilical cord. Stem Cell Rev Rep, 7:17–31.
40.
SalehinejadP, AlitheenNB, AliAM, OmarAR, MohitM, JanzaminE, SamaniFS, TorshiziZ and Nematollahi-MahaniSN. (2012). Comparison of different methods for the isolation of mesenchymal stem cells from human umbilical cord Wharton's jelly. In Vitro Cell Dev Biol Anim, 48:75–83.
41.
MushaharyD, SpittlerA, KasperC, WeberV and CharwatV. (2018). Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A, 93:19–31.
42.
TrounsonA and McDonaldC. (2015). Stem cell therapies in clinical trials: progress and challenges. Cell Stem Cell, 17:11–22.
43.
KlaassenI, Van NoordenCJ and SchlingemannRO. (2013). Molecular basis of the inner blood-retinal barrier and its breakdown in diabetic macular edema and other pathological conditions. Prog Retin Eye Res, 34:19–48.
44.
BharadwajAS, AppukuttanB, WilmarthPA, PanY, StempelAJ, ChippsTJ, BenedettiEE, ZamoraDO, ChoiD, DavidLL and SmithJR. (2013). Role of the retinal vascular endothelial cell in ocular disease. Prog Retin Eye Res, 32:102–180.
45.
EggenhoferE, BenselerV, KroemerA, PoppFC, GeisslerEK, SchlittHJ, BaanCC, DahlkeMH and HoogduijnMJ. (2012). Mesenchymal stem cells are short-lived and do not migrate beyond the lungs after intravenous infusion. Front Immunol, 3:297.
46.
WangX, YinX, SunW, BaiJ, ShenY, AoQ, GuY and LiuY. (2017). Intravenous infusion umbilical cord-derived mesenchymal stem cell in primary immune thrombocytopenia: a two-year follow-up. Exp Ther Med, 13:2255–2258.
47.
OnerA, GonenZB, SinimN, CetinM and OzkulY. (2016). Subretinal adipose tissue-derived mesenchymal stem cell implantation in advanced stage retinitis pigmentosa: a phase I clinical safety study. Stem Cell Res Ther, 7:178.
48.
MangioneCM, LeePP, GutierrezPR, SpritzerK, BerryS, Hays and National Eye Institute Visual Function Questionnaire Field Test IRD. (2001). Development of the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol, 119:1050–1058.
49.
SuzukamoY, OshikaT, YuzawaM, TokudaY, TomidokoroA, OkiK, MangioneCM, GreenJ and FukuharaS. (2005). Psychometric properties of the 25-item National Eye Institute Visual Function Questionnaire (NEI VFQ-25), Japanese version. Health Qual Life Outcomes, 3:65.
50.
SugawaraT, SatoE, BabaT, HagiwaraA, TawadaA and YamamotoS. (2011). Relationship between vision-related quality of life and microperimetry-determined macular sensitivity in patients with retinitis pigmentosa. Jpn J Ophthalmol, 55:643–646.
51.
DeramoVA, CoxTA, SyedAB, LeePP and FekratS. (2003). Vision-related quality of life in people with central retinal vein occlusion using the 25-item National Eye Institute Visual Function Questionnaire. Arch Ophthalmol, 121:1297–1302.
52.
SugawaraT, HagiwaraA, HiramatsuA, OgataK, MitamuraY and YamamotoS. (2010). Relationship between peripheral visual field loss and vision-related quality of life in patients with retinitis pigmentosa. Eye (Lond), 24:535–539.
53.
SumiI, MatsumotoS, OkajimaO and ShiratoS. (2000). The relationship between visual disability and visual scores in patients with retinitis pigmentosa. Jpn J Ophthalmol, 44:82–87.
54.
ZhaoC and IkeyaM. (2018). Generation and applications of induced pluripotent stem cell-derived mesenchymal stem cells. Stem Cells Int, 2018:9601623.
55.
YangH, FengR, FuQ, XuS, HaoX, QiuY, FengT, ZengZ, ChenM and ZhangS. (2019). Human induced pluripotent stem cell-derived mesenchymal stem cells promote healing via TNF-alpha-stimulated gene-6 in inflammatory bowel disease models. Cell Death Dis, 10:718.
56.
FerrerL, KimbrelEA, LamA, FalkEB, ZeweC, JuopperiT, LanzaR and HoffmanA. (2016). Treatment of perianal fistulas with human embryonic stem cell-derived mesenchymal stem cells: a canine model of human fistulizing Crohn's disease. Regen Med, 11:33–43.
JungbluthP, SpitzhornLS, GrassmannJ, TannerS, LatzD, RahmanMS, BohndorfM, WruckW, SagerM, et al. (2019). Human iPSC-derived iMSCs improve bone regeneration in mini-pigs. Bone Res, 7:32.
59.
FrobelJ, HemedaH, LenzM, AbagnaleG, JoussenS, DeneckeB, SaricT, ZenkeM and WagnerW. (2014). Epigenetic rejuvenation of mesenchymal stromal cells derived from induced pluripotent stem cells. Stem Cell Rep, 3:414–422.
60.
SpitzhornLS, MeggesM, WruckW, RahmanMS, OtteJ, DegistiriciO, MeiselR, SorgRV, OreffoROC and AdjayeJ. (2019). Human iPSC-derived MSCs (iMSCs) from aged individuals acquire a rejuvenation signature. Stem Cell Res Ther, 10:100.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
